 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced that new data was presented at the American Association for Cancer Research (AACR...

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Biodesix 17.4M share Secondary priced at $1.15

Biodesix 17.4M share Spot Secondary priced at $1.15

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced the pricing of its underwritten offering of 17,391,832 shares of its common stock...

Biodesix Announces Pricing of Oversubscribed and Upsized Underwritten Offering of Common Stock and Concurrent Private Placement

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 200 points on Friday.
The Dow traded up 1.01% to 38,987.23 while the NASDAQ rose 1.50% to 16,289.37. The...

Gold Surges Over 1%; Biodesix Shares Plummet

Biodesix, Inc. (NASDAQ:BDSX - Get Free Report) saw a significant increase in short interest in March. As of March 15th, there was short interest totalling 181,100 shares, an increase of 12.1% from...

Short Interest in Biodesix, Inc. (NASDAQ:BDSX) Increases By 12.1%

Biodesix enters collaborative research agreement with Memorial Sloan Kettering

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with...

Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions and services company, today provided a corporate update and announced its financial and operating results for the fourth quarter and year...

Biodesix Announces Fourth Quarter and Fiscal Year 2023 Results and Business Highlights

Zicix (OTCMKTS:ZICX  Get Free Report) and Biodesix (NASDAQ:BDSX  Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two...

Head-To-Head Contrast: Zicix (OTCMKTS:ZICX) versus Biodesix (NASDAQ:BDSX)

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Boulder, CO.

Volume (M)	38,236.00
52-Wk High	$2.21
52-Wk Low	$1.03

BDSX Biodesix Inc

About

Feed

News

Earnings

Fundamentals